Squalamine eye drops for “multiple neovascular ophthalmic clinical indications each with sizable commercial markets”? I seriously doubt it. I think the people on this Scientific Advisory Board would know better than the people on the biotech values board whether this eyedrop has a chance to work.Having luminaries on a company’s SAB doesn’t make a bad drug better—see item #14 in #msg-71330113.